Why Precision Oncology Programs Stall After Year One: The Data Infrastructure Problem

Why Precision Oncology Programs Stall After Year One

After the first sequencing cohort is complete and the molecular tumor board is up and running, many precision oncology programs run into operational constraints as they move beyond the pilot phase, particularly around data flows and workflow integration.[1] Precision oncology faces implementation barriers including infrastructure, education, data management, costs, policy, and regulation, and these become more visible as programs scale.[1] The main constraint in many settings is the underlying data infrastructure: pipelines, workflows, and system integrations that were designed for a pilot rather than for sustained clinical operations.[2][3]

This is a pattern reported by many precision oncology programs: a promising pilot phase followed by operational friction that slows momentum just as leadership expectations are peaking.[3] If you're running a precision oncology program, the next sections explain why scaling often stalls and what resilient programs do differently.

The Pilot Phase Is Deceptively Easy

Precision oncology pilots succeed because they're controlled experiments. You select ideal patients, assign dedicated bioinformatics support, hand-process each case through the molecular tumor board, and have a research coordinator tracking every sample. Under those conditions, genomic reports reach clinicians in time to influence treatment decisions, and targeted therapies or trial referrals can be matched for a subset of patients.

Pilot success can mask scaling problems. You're effectively running a boutique operation inside a complex healthcare organization. The moment you try to scale—more patients, more referring oncologists, more active sites, tighter turnaround requirements—the infrastructure that worked for a small number of cases often collapses under its own weight.[3]

The Three Infrastructure Failure Points That Kill Scaling

Across academic medical centers and integrated delivery networks, three recurring infrastructure failure points tend to surface once precision oncology programs move beyond the pilot cohort.[1][3]

Failure Point 1: The Bioinformatics Bottleneck

In the pilot phase, a bioinformatician hand-delivers results to the molecular tumor board. They know every pipeline parameter, every sample quirk, and every clinician's reporting preferences. This model may be workable at low annual volumes; as throughput increases, it becomes a bottleneck.

Many research-origin pipelines start as bespoke workflows that depend heavily on individual expertise rather than on reproducible, documented, automated processes. Best-practice recommendations for precision oncology emphasize automated, validated workflows with defined quality-control gates to support scaling.[4] When the bioinformatician who built the pipeline is also the one running it, scaling requires either hiring more bioinformaticians or building infrastructure that does not require them to be in the loop for every single case.[4]

What sustainable programs do differently:[4]

Invest in validated, automated pipelines with documented QC gates that can run without manual intervention for routine cases
Reserve bioinformatician time for complex cases, novel variants, and pipeline development—not routine case processing
Build escalation protocols that route edge cases to expert review while automatically clearing straightforward cases

The goal isn't to replace bioinformatics expertise. It's to build systems that deploy that expertise efficiently rather than consuming it on every single case.[4]

Failure Point 2: EHR Integration That Doesn't Exist

Genomic reports are only clinically useful if they reach the treating oncologist in their workflow.[3] That means test results need to be integrated into the electronic health record (EHR) in a form that is visible, searchable, and linked to the patient's record, rather than living in separate portals or static PDFs.[3][5]

Organizations that struggle most with precision oncology adoption are often those where genomic data and clinical data live in parallel universes. The bioinformatician generates a report. It goes to the molecular tumor board. The board generates recommendations. Those recommendations may or may not make it into the EHR in a way that is actionable by the treating oncologist.[3][5]

This integration problem has a technical side and an organizational side. Technically, you need structured data flows between your genomics pipeline, your molecular tumor board tooling, and your EHR—preferably with bidirectional links so that clinical context (prior treatments, comorbidities, medication history) can inform genomics analysis.[5] Organizationally, you need clinical champions who own the integration workflow and ensure that recommendations are delivered back to treating teams.[5]

What sustainable programs do differently:[3][5]

Build structured EHR integration from the start, even if it takes longer to get the pilot running
Use established standards and vendor-supported capabilities to encode genomic findings as structured, computable data within the EHR (for example, genomics modules or FHIR-based representations)[5]
Establish clear ownership of the "last mile" problem—getting genomics recommendations to the treating oncologist, not just to the tumor board

Failure Point 3: The Evidence Base That Doesn't Grow

Your molecular tumor board makes treatment recommendations based on the best available evidence. But evidence evolves—new therapies are approved, trial results are published, and biomarker interpretations change over time.[1] Without an explicit process for updating the knowledgebase, the evidence used to guide treatment decisions can become outdated faster than periodic review cycles can capture.

Therapy approvals, trial results, and biomarker interpretation changes mean that institutional knowledgebases require ongoing maintenance to remain current.[1] Operational frameworks for precision oncology increasingly emphasize continuous evidence monitoring: features such as automated alerts when new trial data could affect active treatment recommendations, structured capture of real-world outcomes from treated patients that inform future decisions, and scheduled refresh cycles for clinical knowledgebases have been proposed as part of scalable workflows.[4]

This is where AI-assisted literature monitoring and real-world evidence integration can add practical operational value—as tools for keeping the evidence base current at the pace that clinical decision-making requires, rather than as replacements for clinical judgment.[4]

Real-World Evidence: The Missing Piece in Most Programs

Clinical trials define the standard of care. Real-world evidence (RWE) shows how that standard of care performs in the patients you are actually treating, including populations that differ from trial cohorts in age, comorbidities, prior treatment history, and genomic background.[4] RWE can complement trial data by filling gaps in evidence for underrepresented groups and for settings where randomized trials are not feasible.[4]

Organizations that get the most value from precision oncology are the ones treating real-world evidence as a first-class input to treatment decision-making, not only as an output for health economics or outcomes research.[4][6]

How this works in practice:[4][6]

Capturing structured outcome data from every treated patient, including genomic context, treatment received, response, and duration
Using matched cohort or other comparative analyses to contextualize outcomes for patients who could not access clinical trials
Feeding real-world outcome data back into molecular tumor board deliberations to refine treatment recommendations over time

Proposed measures to support this loop include standardized data entry templates, structured documentation in the EHR, and digital tools that link outcomes data back to decision support systems.[6] The feedback loop between clinical practice and evidence generation is what separates precision oncology programs that improve continuously from those that plateau.[4]

Building for Sustainability: The Decisions That Compound

If you're starting or scaling a precision oncology program, the choices you make in the first year compound in ways that are hard to reverse. Here are the decisions that matter most.

Pipeline architecture matters more than pipeline tool selection. You can run STAR-Fusion, GATK, or a dozen other tools in your genomics pipeline.[7][8] The specific tool matters less than whether your pipeline is documented, versioned, reproducible, and deployable by someone other than its author.[4] Architect for automation, auditability, and handoff, not just for scientific performance.

QC gates are load-bearing infrastructure. Precision oncology programs that scale reliably treat quality control as a hard requirement, using automated gates to prevent low-quality results from reaching clinical review rather than relying on ad hoc manual checks.[4] These QC gates need to be explicit, enforced in software, and tied to clinical decision support so that downstream users can trust the data.

Clinical integration is not optional. If your genomic reports require clinicians to log into a separate system, your program will have adoption problems.[3][5] Treat EHR integration as a core requirement from day one, not a Phase 2 enhancement, and design reporting formats that match how oncologists actually make decisions.[5]

Evidence maintenance is a process, not a project. Your molecular tumor board needs a current evidence knowledgebase. Building it once is a project; keeping it current is an ongoing process that requires dedicated ownership, tooling, and scheduled review cycles.[1][4] Align this process with pharmacy, guideline committees, and informatics so that changes in evidence translate into changes in practice.

---

Ready to Build a Precision Oncology Program That Scales?

At Pi Data Science, we help precision oncology programs move from successful pilots to sustainable operations. We work with bioinformatics teams and clinical leadership to design the data infrastructure — pipelines, EHR integrations, molecular tumor board tooling, and real-world evidence capture — that makes precision oncology reliable at scale. If your program is approaching the Year Two scaling challenge, or if you're planning a new precision oncology initiative and want to build it right from the start, let's talk about your infrastructure roadmap.

---

Sources

[1] PMC/NIH — "Implementation barriers in precision oncology: infrastructure, education, and regulation" — https://pmc.ncbi.nlm.nih.gov/articles/PMC12651332/

[2] AJMC — "No Outcome Without Access: Delivering on the Promise of Cancer Care Equity" — https://www.ajmc.com/view/no-outcome-without-access-delivering-on-the-promise-of-cancer-care-equity

[3] LIV Hospital — "Challenges of Precision Oncology Hurdles" — https://int.livhospital.com/challenges-of-precision-oncology-hurdles/

[4] PMC/NIH — "Real-world evidence and bioinformatics workflows in precision oncology" — https://pmc.ncbi.nlm.nih.gov/articles/PMC12936906/

[5] Association of Community Cancer Centers — "Building a Blueprint for Precision Medicine: Lessons from TriHealth" — https://www.accc-cancer.org/view/building-a-blueprint-for-precision-medicine-lessons-from-trihealth

[6] Frontiers in Digital Health — "Digital tools for structured outcome capture in precision oncology" — https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2026.1828544/full

[7] STAR-Fusion Project — "STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq" — https://github.com/STAR-Fusion/STAR-Fusion

[8] GATK — "Genome Analysis Toolkit" — https://github.com/gatk-suite/gatk